#Ticagrelor Market

[ojaswini8]

Hospital Gowns Market is Estimated to Witness High Growth Owing to Advancements in Healthcare Protection Garments

Hospital Gowns Market is Estimated to Witness High Growth Owing to Growing Patient Volume The hospital gowns market has witnessed significant growth over the past few years owing to the growing need for surgical gowns and patient gowns in hospitals and other healthcare settings. Hospital gowns provide an extra layer of protection and comfort to patients and medical professionals in clinical settings. They protect patients from hospital-acquired infections by preventing the spread of microorganisms from clothes. In addition, hospital gowns provide easy access to patients' back, protect patients' dignity, and allow for monitoring of diagnostic equipment. Get More Insights On Hospital Gowns Market https://www.insightprobing.com/blog/hospital-gowns-market-size-share/ Explore More Report Ticagrelor Market https://www.quora.com/Does-ticagrelor-medicine-prevent-a-heart-attack?q=Does%20ticagrelor%20medicine%20prevent%20a%20heart%20attack%3F Beryllium Market https://www.reddit.com/r/projectozone3/comments/183rqny/how_to_get_beryllium/ Laxatives Market https://www.quora.com/Why-does-xylitol-have-laxative-and-blood-clotting-effects

[atharvacmi]

Ticagrelor Market is Anticipated to Witness Growth Owing to Increasing Prevalence of Cardiovascular Diseases

Ticagrelor is an oral antiplatelet medication used to inhibit blood clots in patients with acute coronary syndromes or a history of myocardial infarction. It is commonly used along with aspirin to prevent heart attacks and strokes in high-risk patients. Ticagrelor works by reversibly binding to the P2Y12 receptor on platelets, reducing platelet aggregation and thrombus formation. The growing prevalence of cardiovascular diseases has increased the demand for antiplatelet drugs like ticagrelor for treatment and prevention of conditions like myocardial infarction and unstable angina.

The Global ticagrelor market is estimated to be valued at US$ 1481.28 Mn in 2024 and is expected to exhibit a CAGR of 3.0% over the forecast period 2024 to 2031. Key Takeaways Key players operating in the ticagrelor market are Atlas Roofing Corporation, BASF SE, Johns Manville, Duro-Last, Inc., E. I. Du Pont De Nemours, Inc., Owens Corning, Sika AG, Standard Industries Inc., and The Dow Chemical Company. These key players are actively focusing on new product developments and geographic expansion to strengthen their presence in the global market. Key opportunities in the ticagrelor market include increasing healthcare spending in emerging economies, improving accessibility of healthcare facilities, rise in approval of new drugs for cardiovascular disorders, and growing geriatric population which is at high risk of cardiovascular diseases. The market players are also exploring opportunities in developing regions like Asia Pacific and Latin America through joint ventures and collaborations with local players.

Atals Roofing Corporation recently expanded its operations in China and India to cater to the burgeoning demand for Ticagrelor Market Size in these lucrative markets. Similarly, BASF SE inaugurated a new production facility in Brazil to capitalize on the opportunities arising due to growing cardio-metabolic disorders in Latin America. These global expansion strategies are anticipated to drive the overall ticagrelor market during the forecast period. Market drivers One of the key drivers of the ticagrelor market is the rising prevalence of cardiovascular diseases worldwide. As per the WHO, cardiovascular diseases are the number one cause of death globally, taking an estimated 17.9 million lives each year. Moreover, increasing adoption of unhealthy lifestyles and growing geriatric population are further contributing to the increasing incidence of myocardial infarction, unstable angina and other cardiac conditions. Since ticagrelor is one of the preferred antiplatelet drugs for managing these conditions, its demand is growing steadily each year. Market restrain Stringent regulations pertaining to drug approval and high costs associated with clinical trials are some of the key factors restraining the growth of ticagrelor market. New drug candidates need to undergo rigorous testing to demonstrate efficacy and safety. Moreover, lengthy approval timelines and high investment requirements pose significant challenges for market players, especially smaller companies and startup firms. Regulatory uncertainty also inhibits market expansion to some extent. Addressing these regulatory challenges would be important for sustained growth of the Ticagrelor Market Size and Trends over the coming years.

Segment Analysis The global ticagrelor market is segmented based on the application, distribution channels and region. Based on application, the market is segmented into acute coronary syndrome, unstable angina pectoris and others. Among these, the acute coronary syndrome dominates the market and accounts for the major share owing to rapidly growing cases of heart attacks every year and preference ticagrelor over other alternatives. Based on distribution channels, the ticagrelor market is categorized into hospital pharmacies, retail pharmacies and online pharmacies. Hospital pharmacies hold the prominent share in the market due to increasing prescription of ticagrelor by cardio specialists for ACS patients. Regional Analysis North America holds the major share in the ticagrelor market due to rise in preference for personalized medicines over traditional approaches and presence of developed healthcare infrastructure and reimbursement policies. Europe is the second largest regional market supported by growing awareness about advantages of ticagrelor over other drugs. Asia Pacific shows fastest growth owing to rapidly increasing geriatric population susceptible to cardiovascular diseases, improving access to healthcare facilities and rise in healthcare spending.

Get More Insights On, Ticagrelor Market

About Author: Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)

[bhushans]

Global Sphingolipids Market: A Deep Dive into Key Drivers and Trends

The global clot-busting drugs market is expected to have a significant increase in market value, reaching approximately USD 28.8 billion in 2022. By the end of 2032, the market is expected to have grown at a solid Compound Annual Growth Rate (CAGR) of 7.3%, propelling it to a valuation of USD 58.4 billion.

Among other thrombotic diseases, thrombolytics—drugs that break up blood clots—are crucial for the treatment of heart attacks, strokes, and pulmonary emboli. These drugs can improve patient outcomes and lower the risk that severe consequences in critical medical conditions will occur by dissolving blood clots and restoring blood flow to injured tissues.

Companies are creating new clot busting medications with fewer side effects and at a lower cost because customers aren’t receiving clot busting medicines as intended because of misconceptions and the treatments’ negative consequences. It is anticipated that this will greatly increase the acceptance and use of clot-busting drugs. Over the anticipated timeframe, increasing product releases and approvals are anticipated to fuel more market expansion.

Gain a Competitive Edge: Request Your Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-15689

Key Takeaways from Market Study

Anticoagulants are the leading segment as a product, and hold approximately 36.7% market share in 2021, due to the rise in chronic diseases, the development of anticoagulant medicines has become more molecularly and biologically advanced, and emerging nations are increasingly using novel oral anticoagulants.

Pulmonary Embolism are the leading segment by indication, and held about 31.2% market share in 2021, owing to the increasing number of cancer patients and patients who have a family history of cardiovascular issues.

Injectable category is the leading segment in route of administration of drugs by holding more than half of the global market share owed to growing need for tools like safety syringes, prefilled syringes, and auto-injectors for the prevention of needle stick injuries.

Hospital Pharmacy is the leading distribution channel as of 2021, withholding about one third of the global market share by value due to wide range of product availability, convenience and patients’ reliance on hospitals for treatments.

By region, North America is leading in the global clot busting drugs market with 32.4% of the revenue share on 2021 and is expected to continue to do so with a projected CAGR rate of 8.0% during the forecasted years.

“Rising initiatives to promote health benefits of clot busting drugs, as well as the increasing awareness about the prevention of heart attacks and strokes is set to propel the sales of clot busting drugs devices across the globe,” says an analyst of Future Market Insights.

Market Competition

The market for clot busting drugs is quite competitive due to the presence of numerous local or regional players. The companies are concentrating on implementing different business strategies, such as product launches, drug development, and geographic expansions. For Instance:

In Dec 2021, Janssen Pharmaceutical received U.S. FDA approval for its oral anticoagulant called XARELTO (rivaroxaban). The drug was approved for 2 indications for pediatric category which includes prophylaxis of DVT or deep vein thrombosis resulting in pulmonary embolism.

AstraZeneca’s Brilinta (ticagrelor) received FDA approval for its P2Y12 receptor antagonist, an oral, reversible drug that prevents platelet activation, in June 2020 to lower the risk of a stroke or a first heart attack in patients with high-risk of coronary artery disease (CAD).

Key Segments Covered in Clot Busting Drugs Industry Research

By Product:

Thrombolytic Drugs

Anti-Platelet Drugs

Anticoagulants

Others

By Indication:

Pulmonary Embolism

Deep Vein Thrombosis

Atrial Fibrillation

Others

By Route of Administration:

Oral

Injectable

By Distribution Channel:

Hospital Pharmacy

Drug Store

Online Pharmacy

Retail Pharmacy

By Region:

North America

Latin America

Europe

East Asia

South Asia

Oceania

Middle-East and Africa (MEA)

[kirancmi]

Antiplatelet Drugs Market To Witness Significant Growth Owing To Rising Prevalence Of Cardiovascular Diseases

Antiplatelet drugs are medications that are used to inhibit blood clot formation by interfering with platelet aggregation and adhesion. These drugs are commonly used for secondary prevention of cardiovascular events such as heart attacks and strokes. Some common antiplatelet medications include aspirin, clopidogrel, ticagrelor, prasugrel, ticlopidine, and others. The antiplatelet drugs market encompasses medication classes such as cyclooxygenase inhibitors, P2Y12 receptor inhibitors, and others. The global antiplatelet drugs market is estimated to be valued at US$ 2674.22 Bn in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights. Market Dynamics: Rising prevalence of cardiovascular diseases is one of the major drivers spurring growth of the antiplatelet drugs market. According to the estimates provided by the World Health Organization, cardiovascular diseases are the leading cause of death globally, accounting for over 17.9 million deaths each year. Growing geriatric population also makes them more prone to cardiovascular disorders. Various awareness campaigns by governments and healthcare organizations regarding benefits of antiplatelet drugs in preventing secondary cardiovascular events are also fueling market growth. Additionally, strong pipeline of novel antiplatelet drugs with better tolerability and efficacy will further aid expansion of the market over the forecast period. However, drug discontinuation and risks of excessive bleeding associated with antiplatelet drugs may hamper market growth to some extent. SWOT Analysis Strength: Antiplatelet drugs reduce cardiovascular disease risks and act as blood thinners by inhibiting platelet aggregation. Leading drugs like clopidogrel, ticagrelor, and prasugrel have strong efficacy and prevent clot formation effectively in three sentences or less. Patent expiries of major drugs between 2014-2020 lowered prices and improved access to therapy. Weakness: Antiplatelet drugs increase risk of bleeding and bruising as a common side effect. Monitoring requirements and contraindications in certain patients undermine full compliance with medication in daily use. Opportunity: Emerging economies are expected to drive volume growth due to increasing healthcare investment and awareness. New formulations focused on enhanced safety, tolerability and convenience represent opportunities. Threats: biosimilars capturing market share threaten revenues of leading brands post-patent expiry. Stringent regulations and clinical trials required for new molecular entities limit the number of novel market entrants. Key Takeaways The global antiplatelet drugs market size is expected to witness high growth. The global Antiviral Drugs Market is estimated to be valued at US$ 2674.22 Bn in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2024-2031.

Regional analysis related content comprises Asia Pacific is projected to be the fastest growing region due to rising medical expenditures, healthcare reforms and growing efforts to expand insurance coverage in major markets like China and India. Key players operating in the antiplatelet drugs market are Chang Chun Group, Covestro AG, Dow, and Hexio. Patent expiries of major drugs between 2014-2020 lowered prices and improved access to therapy globally. Get more insights on this topic: https://www.newsstatix.com/antiplatelet-drugs-market-industry-insights-trends-antiplatelet-drugs-market/

[pranay-234]

Antiplatelet Market: Strategic Imperatives for Success and Rising Demand During 2023-2032

 The global antiplatelet market plays a critical role in preventing and managing cardiovascular diseases, which remain a leading cause of mortality worldwide. Antiplatelet medications have come a long way in reducing the risk of blood clot formation and, consequently, the incidence of heart attacks and strokes. In this article, we delve into the trends, key drivers, and the future prospects of the global antiplatelet market, shedding light on the dynamic landscape of this essential therapeutic sector.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭 : https://www.alliedmarketresearch.com/request-sample/10844

Trends in the Antiplatelet Market

Growing Awareness and Adoption: One of the notable trends in the antiplatelet market is the increasing awareness among both healthcare professionals and patients about the importance of antiplatelet therapy. As knowledge about the benefits of these medications in preventing cardiovascular events spreads, more patients are being prescribed antiplatelet drugs as part of their treatment regimens.

Advancements in Drug Development: The market is witnessing a continuous stream of innovations in antiplatelet drug development. Newer, more potent antiplatelet agents are being introduced, offering better efficacy with reduced side effects. Additionally, research into personalized antiplatelet therapy based on genetic and clinical factors is gaining ground.

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰

Type of Antiplatelet Medications:

Aspirin (Acetylsalicylic Acid): Aspirin remains one of the most widely used antiplatelet drugs and is commonly prescribed for the prevention of cardiovascular events.

P2Y12 Inhibitors: This class includes drugs like clopidogrel, prasugrel, and ticagrelor, which are often used in combination with aspirin to prevent stent thrombosis and manage acute coronary syndromes.

GP IIb/IIIa Inhibitors: Medications like abciximab, eptifibatide, and tirofiban are used in hospital settings during percutaneous coronary interventions (PCI) to prevent platelet aggregation.

Indications and Applications:

Primary Prevention: Antiplatelet drugs are prescribed for individuals at high risk of cardiovascular events, such as those with multiple risk factors but no prior history of heart disease.

Secondary Prevention: Patients with a history of heart attacks, strokes, or peripheral arterial disease often receive antiplatelet therapy to prevent recurrent events.

Other Medical Fields: Antiplatelet drugs are also utilized in conditions beyond cardiology, including neurology for the prevention of stroke and in certain cancer treatments.

Distribution Channels:

Hospital Pharmacies: Many antiplatelet drugs are administered in a hospital setting, especially in cases of acute coronary syndromes and surgeries, where immediate platelet inhibition is required.

Retail Pharmacies: These are key distribution points for antiplatelet medications prescribed for long-term use, such as in the prevention of recurrent cardiovascular events.

Online Pharmacies: With the increasing trend of online healthcare services, antiplatelet medications are also available through digital platforms, offering convenience to patients for prescription refills and consultations.

𝐏𝐫𝐞-𝐛𝐨𝐨𝐤 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐍𝐨𝐰 : https://www.alliedmarketresearch.com/antiplatelet-market/purchase-options

Drivers of the Antiplatelet Market

Rising Cardiovascular Disease Burden: Cardiovascular diseases, including heart attacks and strokes, continue to be a major global health concern. The increasing incidence of these conditions is a significant driver for the antiplatelet market. As the global population ages and lifestyles change, the demand for antiplatelet therapies is on the rise.

Advancing Healthcare Infrastructure: Developing and emerging economies are witnessing improvements in their healthcare infrastructure. This includes better access to healthcare services, diagnostics, and medications, including antiplatelet drugs. As healthcare systems become more robust, the availability and affordability of these medications are expanding.

Future Prospects of the Antiplatelet Market

Personalized Medicine in Antiplatelet Therapy: The future of antiplatelet therapy is likely to be highly personalized. With advances in genetic testing and a deeper understanding of how individuals respond to these medications, tailoring antiplatelet regimens to each patient's unique profile will become the norm. This approach will maximize the benefits of therapy while minimizing potential risks.

Expansion Beyond Cardiovascular Care: While cardiovascular care will remain a primary focus, antiplatelet drugs may find applications in other medical fields. Research is ongoing into the potential use of antiplatelet agents in cancer prevention and treatment, neurology, and even in infectious disease management.

Global Market Growth: The global antiplatelet market is expected to grow significantly in the coming years. The increasing prevalence of cardiovascular diseases, coupled with ongoing research and development efforts, will drive the market's expansion. Moreover, the introduction of cost-effective generic versions of antiplatelet drugs will enhance accessibility.

𝐈𝐧𝐭𝐞𝐫𝐞𝐬𝐭𝐞𝐝 𝐭𝐨 𝐏𝐫𝐨𝐜𝐮𝐫𝐞 𝐭𝐡𝐞 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭? 𝐈𝐧𝐪𝐮𝐢𝐫𝐞 𝐁𝐞𝐟𝐨𝐫𝐞 𝐁𝐮𝐲𝐢𝐧𝐠 : https://www.alliedmarketresearch.com/purchase-enquiry/10844

Conclusion

The global antiplatelet market is poised for growth, driven by increasing awareness, ongoing drug development, and the ever-present burden of cardiovascular diseases. As healthcare systems worldwide continue to evolve, antiplatelet therapy will remain a cornerstone in the prevention and management of these conditions. The future holds promise for more effective, personalized treatment regimens, expanding applications in various medical fields, and improved global access to these vital medications. In the fight against cardiovascular diseases, antiplatelet drugs will continue to be a key ally.

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

[myblogscmi]

U.S. P2Y12 Inhibitors Market Is Estimated To Witness High Growth Owing To Increasing Demand for Antiplatelet Drugs

The U.S. P2Y12 inhibitors market is estimated to be valued at US$215.7 Million In 2021 and is expected to exhibit a CAGR of 3.8% over the forecast period, according to a new report published by Coherent Market Insights. The market for P2Y12 inhibitors is driven by the increasing demand for antiplatelet drugs, which are used to prevent blood clotting in individuals with a history of cardiovascular diseases or recent heart surgeries. P2Y12 inhibitors are specifically designed to block the action of the P2Y12 receptor on platelets, thereby reducing the risk of clot formation. Market Key Trends: Rising Focus on Personalized Medicine One key trend in the U.S. P2Y12 Inhibitors Market is the rising focus on personalized medicine. With advancements in molecular diagnostics and genetic testing, healthcare providers are increasingly adopting personalized medicine approaches to optimize treatment outcomes for their patients. In the case of P2Y12 inhibitors, genetic testing can help identify individuals who are poor metabolizers of certain antiplatelet drugs, such as clopidogrel. This information enables healthcare providers to personalize the dosage or switch to alternative drugs for optimal therapeutic efficacy. For example, individuals carrying loss-of-function alleles for the CYP2C19 gene are poor metabolizers of clopidogrel, which is a widely prescribed P2Y12 inhibitor. These individuals have a significantly higher risk of major cardiovascular events, such as stent thrombosis, compared to normal metabolizers. By identifying these individuals through genetic testing, healthcare providers can prescribe alternative P2Y12 inhibitors, such as prasugrel or ticagrelor, which have shown better clinical outcomes in poor metabolizers. PEST Analysis: Political: The U.S. P2Y12 inhibitors market is influenced by government regulations and policies related to drug approval, pricing, and reimbursement. Stringent regulations ensure the safety and efficacy of these drugs in the market. Economic: The economic factors impacting the market include healthcare expenditure, insurance coverage, and affordability of P2Y12 inhibitors for patients. The high cost of these drugs can limit their accessibility to a certain population. Social: The social factors influencing the market include the prevalence of cardiovascular diseases, awareness among patients about antiplatelet drugs, and patient adherence to prescribed treatments. Technological: Advancements in diagnostic technologies, such as genetic testing, and drug delivery systems are driving innovation in the P2Y12 inhibitors market. These advancements enable personalized medicine approaches and improve patient outcomes. Key Takeaways: - The U.S. P2Y12 Inhibitors Market is expected to witness high growth, exhibiting a CAGR of 3.8% over the forecast period, due to increasing demand for antiplatelet drugs. - Regional Analysis: North America is expected to dominate the U.S. P2Y12 inhibitors market, owing to the high prevalence of cardiovascular diseases in the region and well-established healthcare infrastructure. Furthermore, increasing government initiatives for cardiovascular disease prevention and management contribute to the market growth. - Key Players: Key players operating in the U.S. P2Y12 inhibitors market include Mylan N.V., Bristol-Myers Squibb, Dr Reddy's Laboratories, Teva Pharmaceuticals USA, Inc., AstraZeneca, Genentech, Eli Lilly and Company, Panacea Biotec, CHIESI USA, Inc., Lupin, Cipla, and Biocon. These companies focus on strategic collaborations, product launches, and acquisitions to expand their product portfolios and strengthen their market presence. In conclusion, the U.S. P2Y12 inhibitors market is expected to witness significant growth due to the increasing demand for antiplatelet drugs. The market is driven by the rising focus on personalized medicine, wherein genetic testing helps optimize treatment outcomes. North America is anticipated to dominate the market, and key players are actively involved in strategic initiatives to strengthen their position in the market.

[rohans18]

Antiplatelet Drugs Market Applications and Current Status

Global Antiplatelet Drugs Market, By Drug (Aspirin, Clopidogrel, Ticagrelor, Prasugrel, Others), Indication (Myocardial Infraction, Percutaneous Coronary Interventions, Arterial Thrombosis, Others), Route of Administration (Oral, Injectable), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.

In the consistent Antiplatelet Drugs market research report, industry trends are put together on macro level with which clients can figure out market landscape and possible future issues about Antiplatelet Drugs industry. The scope of this market report include but is not limited to latest trends, market segmentation, new market entry, industry forecasting, future directions, opportunity identification, strategic analysis and planning, target market analysis, insights and innovation. The report presents with the CAGR value fluctuations for the specific forecasted period which helps decide costing and investment strategies. An influential Antiplatelet Drugs market report brings precise and exact market research information that drives business into the right direction.

Key Players

Swedish Orphan Biovitrum AB (Sweden)

MEDIPOST Co., Ltd. (South Korea)

Zimmer Biomet (US)

B. Braun Melsungen AG (Germany)

Stryker Corporation (US)

Smith & Nephew plc (UK)

Medtronic (US)

CONMED Corporation. (US)

DePuy Synthes (US)

Arthrex, Inc. (US)

 Browse More Info @ https://www.databridgemarketresearch.com/reports/global-antiplatelet-drugs-market

The research studies entailed in the winning Antiplatelet Drugs market report supports to estimate several important aspects that includes but are not limited to investment in a rising market, success of a new product, and expansion of market share. The strategies underlined here mainly consist of new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others that boost footprints in this market. Several other factors such as import, export, gross margin, price, cost, and consumption are also analyzed under the section of production, supply, sales and market status.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Antiplatelet Drugs Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03:  Global Market

Part 04: Global Market Size

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

 More Reports:

Diuretic Drugs Market

Patient Engagement Technology Market

Healthcare Business Intelligence Market

Chinese Hamster Ovary cells (CHO) Market

Anti-cancer Drug Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

[myabhijitr]

Ticagrelor Market - Size, Share, Outlook, and Analysis, 2018-2026

Ticagrelor is used along with aspirin to prevent serious life-threatening problems associated with heart and blood vessels in people suffering with heart attack or severe chest pain. It is also used to prevent development of blood clots with coronary stents in patients having history of heart attack or severe chest pain. The global ticagrelor market is expected to grow at a significant growth rate during the forecast period, owing to high patient pool suffering from heart problems, increasing generic drug development, and improving market access scenarios.

Get PDF Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2515

Increasing burden of heart diseases has direct impact on global morbidity and mortality. For instance, according to American Heart Association and America Stroke Association report 2017 statistics update, cardiovascular disease is listed as the underlying cause of death, accounted for nearly 801,000 deaths in 2017, causing about 1 of every 3 deaths in the U.S. Same source also stated that about 92.1 million American adults were living with some form of cardiovascular disease or the after-effects of stroke in 2017.

Moreover, significant increase in the number of approvals from the U.S. Food and Drug Administration (USFDA) for ticagrelor will aid in the growth of ticagrelor market during the forecast period. For instance, in July 2018, USFDA permitted approval for ticagrelor tablets, manufactured by Alembic Pharmaceuticals, to reduce the rate of cardiovascular deaths and stroke in patients with acute coronary syndrome (ACS), or a history of myocardial infarction (MI).

Report with Discount Available @ https://www.coherentmarketinsights.com/insight/request-discount/2515

Furthermore, instances of product failures will hamper growth of the ticagrelor market during the forecast period. For instance, in October 2016, drug Brilinta containing 90 mg ticagrelor manufactured by AstraZeneca plc failed to demonstrate its benefit over clopidogrel for a new indication in peripheral artery disease (PAD). This led to decreased shares of Brilinta by 1% in October 2016.

North America holds the chief stake in the ticagrelor market, owing to increase in mergers and acquisitions of key players. For instance, in November 2017, PhaseBio Pharmaceuticals, Inc. entered into an exclusive, worldwide license agreement with MedImmune, the global biologics research and development arm of AstraZeneca, for PB2452 (formerly MEDI2452), a phase 1-ready reversal agent for ticagrelor. Ticagrelor binds reversibly with the receptors present on platelets.

Europe is also expected to observe significant growth in the global ticagrelor market, owing to increasing approvals for new ticagrelor formulation development in the region. For instance, in May 2017, the European Commission granted marketing authorization for AstraZeneca’s Brilique (ticagrelor) orodispersible tablets (ODT) as a new method of treatment administration. This tablet is effective for patients with difficulty in swallowing and in emergency cases.

Click To Continue Reading On Ticagrelor Market

Key players operating in the ticagrelor market include C.H. Boehringer Sohn AG & Ko. KG, Pfizer Inc., Eli Lilly and Company, AstraZeneca plc, Natco Pharma Limited, Anhui Haikang Pharmaceutical Co., Ltd., Avra Laboratories Pvt. Ltd., and Sun Pharmaceutical Industries Ltd.

About Coherent Market Insights:

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link :https://www.coherentmarketinsights.com/phase-xs,

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

[bhushans]

Beyond Diagnosis: Exploring Global clot busting drugs market

The global clot busting drugs market size is projected to increase at a compound annual growth rate (CAGR) of 7.3% to reach US$ 58.4 billion by the end of 2032, from an estimated US$ 28.8 billion in 2022. The injectable mode of administration is leading the global market for clot-busting medications as of 2021.

Due to the quick development of clot-busting medication's molecular and biological customisation as well as the rising incidence of cardiovascular illnesses and aging population globally, the market for these medications is growing quickly on a global scale. The market for clot-busting medications is anticipated to develop significantly over the projected years as a result of the rising demand for these medications in the prevention of heart attacks and strokes. Due to side effects and lack of knowledge, clot busting treatments are not meeting consumer demand, hence businesses are coming out with new, reasonably priced clot busting drugs with less adverse effects. It is anticipated that this will greatly increase the uptake and intake of medications that break blood clots. The rising product launches and approvals are expected to further contribute to the market growth over the forecast period.

Get a Sample Copy of the Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-15689

Key Takeaways from Market Study

Anticoagulants are the leading segment as a product, and hold approximately 36.7% market share in 2021, due to the rise in chronic diseases, the development of anticoagulant medicines has become more molecularly and biologically advanced, and emerging nations are increasingly using novel oral anticoagulants.

Pulmonary Embolism are the leading segment by indication, and held about 31.2% market share in 2021, owing to the increasing number of cancer patients and patients who have a family history of cardiovascular issues.

Injectable category is the leading segment in route of administration of drugs by holding more than half of the global market share owed to growing need for tools like safety syringes, prefilled syringes, and auto-injectors for the prevention of needle stick injuries.

Hospital Pharmacy is the leading distribution channel as of 2021, withholding about one third of the global market share by value due to wide range of product availability, convenience and patients’ reliance on hospitals for treatments.

By region, North America is leading in the global clot busting drugs market with 32.4% of the revenue share on 2021 and is expected to continue to do so with a projected CAGR rate of 8.0% during the forecasted years.

“Rising initiatives to promote health benefits of clot busting drugs, as well as the increasing awareness about the prevention of heart attacks and strokes is set to propel the sales of clot busting drugs devices across the globe,” says an analyst of Future Market Insights.

Market Competition

The market for clot busting drugs is quite competitive due to the presence of numerous local or regional players. The companies are concentrating on implementing different business strategies, such as product launches, drug development, and geographic expansions. For Instance:

In Dec 2021, Janssen Pharmaceutical received U.S. FDA approval for its oral anticoagulant called XARELTO (rivaroxaban). The drug was approved for 2 indications for pediatric category which includes prophylaxis of DVT or deep vein thrombosis resulting in pulmonary embolism.

AstraZeneca’s Brilinta (ticagrelor) received FDA approval for its P2Y12 receptor antagonist, an oral, reversible drug that prevents platelet activation, in June 2020 to lower the risk of a stroke or a first heart attack in patients with high-risk of coronary artery disease (CAD).

Key Segments Covered in Clot Busting Drugs Industry Research

By Product:

Thrombolytic Drugs

Anti-Platelet Drugs

Anticoagulants

Others

By Indication:

Pulmonary Embolism

Deep Vein Thrombosis

Atrial Fibrillation

Others

By Route of Administration:

Oral

Injectable

By Distribution Channel:

Hospital Pharmacy

Drug Store

Online Pharmacy

Retail Pharmacy

By Region:

North America

Latin America

Europe

East Asia

South Asia

Oceania

Middle-East and Africa (MEA)

[jesse-pinkman123]

The Global Ticagrelor Industry sector is the focus of Ticagrelor Market Research. The current industry scenario was examined, as well as future industry projections. The market research report evaluates a variety of relevant aspects

[shruticmi]

The Global Ticagrelor Market to surpass at US$ 1,145.0 million in 2017.

Summary:The Global Ticagrelor Market is expected to witness a CAGR of 12.3% during the forecast period.

Market Overview:

Ticagrelor is an anti-platelet drug which decreases the platelet aggregation and prevents blood clots to prevent coronary stents in patients having history of heart attack or severe chest pain.

Download the PDF Brochure on The Global Ticagrelor Market here

The global ticagrelor market is expected to grow at a significant growth rate during the forecast period, owing to high patient pool suffering from heart problems, increasing generic drug development, and improving market access scenarios.

Rising number of approvals from the U.S. Food and Drug Administration (USFDA) for ticagrelor will resulted in the growth of ticagrelor market during the forecast period.

Market Trends:

According to the American Heart Association,approximately USD 555 billion was spent in the Americas for the treatment of cardiovascular disorders.

For instance, according to the American Heart Association, in 2014, around 31% of the deaths in the US were due to cardiovascular disorders.

The rising patient population of strokes and cardiovascular disorders, increasing research on antiplatelets, availability of advanced treatment facilities, increasing healthcare expenditure, and introduction of advanced and integrated treatment options into the market along with the presence of good healthcare infrastructure are the major factors behind the fuel growth of the market.

Competitive Landscape

Key players operating in the ticagrelor market include C.H. Boehringer Sohn AG & Ko. KG, Pfizer Inc., Eli Lilly and Company, AstraZeneca plc, Natco Pharma Limited, Anhui Haikang Pharmaceutical Co., Ltd., Avra Laboratories Pvt. Ltd., and Sun Pharmaceutical Industries Ltd

Market Segmentation:

By Route of Application

Acute Coronary Syndrome

Heart Surgeries

Angioplasty

Stent Placement

Coronary Artery Bypass Graft

By End User

Hospitals & Clinics

Ambulatory Centers

Others

By Region 

US 

Canada

Germany 

UK 

France 

Italy 

Spain 

Rest of Western Europe

China 

Japan

India 

Australia 

South Korea 

Rest of Asia-Pacific

Middle East 

Africa

Buy Now the Research Report on The Global Ticagrelor Market

Related Topics:

Healthcare Contract Research Outsourcing Market Analaysis

Healthcare Contract Research Outsourcing is conducted by pharmaceutical and medical device sectors for development of new drugs and medical devices. Clinical trials form the key part of pharmaceutical drug and medical device development and in the current scenario clinical trials are conducted across multiple locations in various geographies. Increasing cost and time required for drug development is expected to propel growth of the global healthcare contract research outsourcing market over the forecast period.

North America Wound Debridement Products Market Analysis

Increasing diseases in North America are particularly ulcers attributed to either diabetes, venous disease, or arterial disease has been observed to be major factor for the market growth. Increasing cost and time required for drug development is expected to propel growth of the global healthcare contract research outsourcing market over the forecast period.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

Contact Us:

Mr. Shah

Coherent Market Insights Pvt.Ltd.

Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. 

Phone: +1-206-701-6702

Email:sales@coherentmarketinsights.com

Reference:Coherent Market insight

[reportsandmarkets]

Ticagrelor Market 2017 Share, Growth, Key Manufacturers Analysis and Regional Forecast

Ticagrelor Market 2017 Share, Growth, Key Manufacturers Analysis and Regional Forecast

About: Ticagrelor Market Complete Report @ https://www.reportsandmarkets.com/reports/global-ticagrelor-market-professional-survey-report-2017-1623014 The Reports and Market Provide this report about Ticagrelor in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016,��